Chiesi to acquire KalVista in $1.9 billion rare disease deal

Chiesi Group said it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, adding KalVista’s hereditary angioedema franchise to Chiesi’s rare disease portfolio. Under the April 29, 2026 merger agreement, Chiesi plans to launch a tender offer for all outstanding KalVista shares at $27.00 per share in cash, a 36% premium to KalVista’s 30-day volume-weighted average share price as of April 28. The deal centers on EKTERLY (sebetralstat), KalVista’s oral on-demand treatment for acute hereditary angioedema attacks, which won FDA approval on July 3, 2025, as the first and only oral on-demand option in the category. (ir.kalvista.com)

Why it matters: For veterinary professionals, this is mainly a signal about where biopharma capital is moving: toward rare disease assets with differentiated delivery, established regulatory momentum, and room for global expansion. While the transaction is in human health, it reflects the same market logic seen across animal health and specialty therapeutics, where companies are paying for late-stage or newly launched products that can change care pathways and strengthen niche portfolios. Chiesi and KalVista both framed the acquisition around expanding rare disease reach, and KalVista’s filings note that future value will depend on commercialization of EKTERLY, additional foreign approvals, and ongoing studies including pediatric programs. (ir.kalvista.com)

What to watch: The next milestone is the formal tender offer and related SEC filings, with closing expected in the third quarter of 2026 if customary conditions are met. (kirkland.com)